Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties

PA Harnedy, Vadivel Parthsarathy, CM McLaughlin, MB O'Keeffe, Philip Allsopp, E. M. McSorley, Finbarr O'Harte, RJ Fitzgerald

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A blue whiting (Micromesistius poutassou) protein hydrolysate generated using Alcalase 2.4L and Flavourzyme 500L and its simulated gastrointestinal digestion (SGID) sample was assessed for antidiabetic potential in vitro and in vivo. In addition to inhibiting dipeptidyl peptidase-IV (DPP–IV), the hydrolysates mediated insulin and glucagon-like peptide-1 (GLP-1) release from BRIN-BD11 and GLUTag cells, respectively. No significant difference was observed in insulinotropic and DPP-IV inhibitory activity following SGID, while GLP-1 secretion increased significantly (p <0.01). SGID resulted in a significant increase in membrane potential, intracellular calcium and cyclic AMP concentration (p <0.001) versus a glucose control, indicating that insulin secretion may be mediated by the KATP channel-dependent and the protein kinase A pathways. Additionally, acute (90–120min) and persistent (4h) glucose-lowering effects of the blue whiting hydrolysate were observed in normal healthy mice. These results demonstrate that the blue whiting protein hydrolysate had significant metabolic effects relevant to glucose control in vivo.
LanguageEnglish
Pages137-145
Number of pages8
JournalJournal of Functional Foods
Volume40
Early online date10 Nov 2017
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Protein Hydrolysates
Muscle Proteins
Hypoglycemic Agents
Digestion
Glucagon-Like Peptide 1
Glucose
Insulin
Subtilisins
Dipeptidyl Peptidase 4
KATP Channels
Cyclic AMP-Dependent Protein Kinases
Cyclic AMP
Membrane Potentials
Calcium
In Vitro Techniques

Keywords

  • Blue whiting
  • Protein hydrolysate
  • Antidiabetic
  • Functional food
  • Amino acid analysis
  • Peptide identification

Cite this

@article{1556c7448aba469f8392a5e837c6c403,
title = "Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties",
abstract = "A blue whiting (Micromesistius poutassou) protein hydrolysate generated using Alcalase 2.4L and Flavourzyme 500L and its simulated gastrointestinal digestion (SGID) sample was assessed for antidiabetic potential in vitro and in vivo. In addition to inhibiting dipeptidyl peptidase-IV (DPP–IV), the hydrolysates mediated insulin and glucagon-like peptide-1 (GLP-1) release from BRIN-BD11 and GLUTag cells, respectively. No significant difference was observed in insulinotropic and DPP-IV inhibitory activity following SGID, while GLP-1 secretion increased significantly (p <0.01). SGID resulted in a significant increase in membrane potential, intracellular calcium and cyclic AMP concentration (p <0.001) versus a glucose control, indicating that insulin secretion may be mediated by the KATP channel-dependent and the protein kinase A pathways. Additionally, acute (90–120min) and persistent (4h) glucose-lowering effects of the blue whiting hydrolysate were observed in normal healthy mice. These results demonstrate that the blue whiting protein hydrolysate had significant metabolic effects relevant to glucose control in vivo.",
keywords = "Blue whiting, Protein hydrolysate, Antidiabetic, Functional food, Amino acid analysis, Peptide identification",
author = "PA Harnedy and Vadivel Parthsarathy and CM McLaughlin and MB O'Keeffe and Philip Allsopp and McSorley, {E. M.} and Finbarr O'Harte and RJ Fitzgerald",
note = "Compliant in UIR; evidence uploaded to 'Other files'",
year = "2018",
month = "1",
doi = "10.1016/j.jff.2017.10.045",
language = "English",
volume = "40",
pages = "137--145",
journal = "Journal of Functional Foods",
issn = "1756-4646",
publisher = "Elsevier",

}

Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties. / Harnedy, PA; Parthsarathy, Vadivel; McLaughlin, CM; O'Keeffe, MB; Allsopp, Philip; McSorley, E. M.; O'Harte, Finbarr; Fitzgerald, RJ.

In: Journal of Functional Foods, Vol. 40, 01.2018, p. 137-145.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties

AU - Harnedy, PA

AU - Parthsarathy, Vadivel

AU - McLaughlin, CM

AU - O'Keeffe, MB

AU - Allsopp, Philip

AU - McSorley, E. M.

AU - O'Harte, Finbarr

AU - Fitzgerald, RJ

N1 - Compliant in UIR; evidence uploaded to 'Other files'

PY - 2018/1

Y1 - 2018/1

N2 - A blue whiting (Micromesistius poutassou) protein hydrolysate generated using Alcalase 2.4L and Flavourzyme 500L and its simulated gastrointestinal digestion (SGID) sample was assessed for antidiabetic potential in vitro and in vivo. In addition to inhibiting dipeptidyl peptidase-IV (DPP–IV), the hydrolysates mediated insulin and glucagon-like peptide-1 (GLP-1) release from BRIN-BD11 and GLUTag cells, respectively. No significant difference was observed in insulinotropic and DPP-IV inhibitory activity following SGID, while GLP-1 secretion increased significantly (p <0.01). SGID resulted in a significant increase in membrane potential, intracellular calcium and cyclic AMP concentration (p <0.001) versus a glucose control, indicating that insulin secretion may be mediated by the KATP channel-dependent and the protein kinase A pathways. Additionally, acute (90–120min) and persistent (4h) glucose-lowering effects of the blue whiting hydrolysate were observed in normal healthy mice. These results demonstrate that the blue whiting protein hydrolysate had significant metabolic effects relevant to glucose control in vivo.

AB - A blue whiting (Micromesistius poutassou) protein hydrolysate generated using Alcalase 2.4L and Flavourzyme 500L and its simulated gastrointestinal digestion (SGID) sample was assessed for antidiabetic potential in vitro and in vivo. In addition to inhibiting dipeptidyl peptidase-IV (DPP–IV), the hydrolysates mediated insulin and glucagon-like peptide-1 (GLP-1) release from BRIN-BD11 and GLUTag cells, respectively. No significant difference was observed in insulinotropic and DPP-IV inhibitory activity following SGID, while GLP-1 secretion increased significantly (p <0.01). SGID resulted in a significant increase in membrane potential, intracellular calcium and cyclic AMP concentration (p <0.001) versus a glucose control, indicating that insulin secretion may be mediated by the KATP channel-dependent and the protein kinase A pathways. Additionally, acute (90–120min) and persistent (4h) glucose-lowering effects of the blue whiting hydrolysate were observed in normal healthy mice. These results demonstrate that the blue whiting protein hydrolysate had significant metabolic effects relevant to glucose control in vivo.

KW - Blue whiting

KW - Protein hydrolysate

KW - Antidiabetic

KW - Functional food

KW - Amino acid analysis

KW - Peptide identification

U2 - 10.1016/j.jff.2017.10.045

DO - 10.1016/j.jff.2017.10.045

M3 - Article

VL - 40

SP - 137

EP - 145

JO - Journal of Functional Foods

T2 - Journal of Functional Foods

JF - Journal of Functional Foods

SN - 1756-4646

ER -